Additional possibilities for correction of movement disorders induced by neuroleptics in patients with schizophrenia

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 2013, Issue 11, 2013, Pages 78-80

  Semenikhin, D G ^a   Kuchayeva, A V ^a   Karpov, A M ^a   Mikhailova, E B ^a   Murav'eva, A V ^b  

^a KAZAN STATE MEDICAL ACADEMY   (Russian Federation)

^b Bekhterew Clinical Psychiatric Hospital   (Russian Federation)

Author keywords

Extrapyramidal side effects; Neuroleptics; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; CORTEXIN; PEPTIDE;

HUMAN; MOTOR DYSFUNCTION; NOTE; SCHIZOPHRENIA; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRAPYRAMIDAL SYNDROME; FEMALE; MALE; MIDDLE AGED; PARANOID SCHIZOPHRENIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PEPTIDES; QUALITY OF LIFE; SCHIZOPHRENIA, PARANOID; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904856043     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Brown P., Steiger M. J., Thompson P. D. et al. Effectiveness of piracetam in cortical myoclonus. Movement Disorders: official journal of the Movement Disorder Society 1993; 8: 1: 63-68.
2. Israel L., Melac M., Milinkevitch D., Dubos G. Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment. International Psychogeriatrics 1994; 6: 155-170.
3. Kabes J., Sikora J., Pisvejc J. et al. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. International Pharmacopsychiatry 1982; 17: 185-192.
4. Koskiniemi M., Van Vleymen B., Hakamies L. et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurology, Neurosurgery and Psychiatry 1998; 64: 344-348.
5. Noorbala A. A., Akhondzadeh S., Davari-Ashtiani R. et al. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clinical Pharmacy and Therapeutics 1999; 24: 369-374.
6. Sikora J., Kabes J., Pisvejc J. Management of neuroleptic side-effects with piracetam. Ceskoslovenska Psychiatrie 1981; 77: 137-142.